New shorter chemo combo shows promise for hodgkin lymphoma
NCT ID NCT07002216
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing a shortened course of a drug combination called BrECADD for people with advanced Hodgkin lymphoma. The goal is to see if a shorter treatment can still control the cancer while reducing side effects. About 48 adults aged 18 to 60 will receive up to four cycles of the therapy. The study also looks at a blood test to track how well the treatment is working.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone (BrECADD)
- What this could lead to
- If successful, this could offer a shorter, more tolerable chemotherapy regimen for advanced Hodgkin lymphoma, potentially reducing side effects while maintaining effectiveness.
- What could go wrong
- This is a small, early-phase trial with only 48 participants, so results may not apply to all patients. The drug combination still carries significant side effects, and it is not yet known if it works better than standard treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Miami
RECRUITINGMiami, Florida, 33146, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can a smart immune cell with a kill switch beat tough lymphomas?
- Can a new nucleotide analogue boost cancer treatment?
- Can a drug duo outsmart resistant lymphomas?